Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS).
1. The pharmacokinetics of Dala1-peptide T-NH2 (peptide T) was determined during phase I clinical trials in patients with acquired immunodeficiency disease (AIDS) and AIDS related complex (ARC). Drug levels were determined by specific RIA, and in some cases with HPLC analysis, after intravenous (i.v.) or intranasal (i.n.), via metered sprayer, administration. 2. The plasma kinetics appeared to be bi-phasic with a first compartment half-life of 30 to 60 minutes and a second plasma clearance rate of 4 to 6 hours, observed for both routes of administration. Peptide T, in one individual was confirmed to be present at 6 hrs in plasma, determined after HPLC isolation followed by specific RIA. 3. Bioavailability, determined for a 2 mg test dose in six individuals was 9.3 +/- 6.9 nmol/L. Peak plasma levels of 41 +/- 30 nmol/L after 10 mg i.n., 2.8 +/- 5.9 nmol/L after 2 mg i.n., and 0.13 +/- 0.07 nmol/L after 0.4 mg i.n. were observed. In two individuals tested, peptide T was detected in CSF at levels 20% of the corresponding plasma level 90 and 145 minutes post i.v. administration. Peptide T was not detected in urine. I.N. administration was well tolerated for times up to 21 months.
Ruff
M R
MR
Integra Institute, Potomac, MD.
Smith
C
C
Kingan
T
T
Jaffe
H
H
Heseltine
P
P
Gill
M A
MA
Mayer
K
K
Pert
C B
CB
Bridge
T P
TP
D000163:Acquired Immunodeficiency Syndrome / Q000378:metabolism*; D000281:Administration, Intranasal; D001682:Biological Availability; D002490:Central Nervous System / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D015717:Peptide T / Q000134:cerebrospinal fluid / Q000276:immunology / Q000493:pharmacokinetics*; D011863:Radioimmunoassay
D015717:Peptide T